Quantification of I-123-meta-iodobenzylguanidine Heart-to-mediastinum Ratios: Not So Simple After All

Overview

Journal J Nucl Cardiol

Specialty Cardiology & Vascular Diseases

Date 2014 Jul 10

PMID 25005347

Citations 7

Authors

Piotr J Slomka

Puja K Mehta

Guido Germano

Daniel S Berman

Affiliations

Soon will be listed here.

Citing Articles

Cardiac I-MIBG normal uptake values are population-specific: Results from a cohort of controls over 60 years of age.

Roberts G, Lloyd J, Kane J, Durcan R, Lawley S, Howe K J Nucl Cardiol. 2019; 28(4):1692-1701.

PMID: 31529384 DOI: 10.1007/s12350-019-01887-6.

Uptake Index of I-metaiodobenzylguanidine Myocardial Scintigraphy for Diagnosing Lewy Body Disease.

Kamiya Y, Ota S, Okumiya S, Yamashita K, Takaki A, Ito S Asia Ocean J Nucl Med Biol. 2017; 5(1):37-43.

PMID: 28840137 PMC: 5221684. DOI: 10.22038/aojnmb.2016.7972.

Cross calibration of I-meta-iodobenzylguanidine heart-to-mediastinum ratio with D-SPECT planogram and Anger camera.

Nakajima K, Okuda K, Yokoyama K, Yoneyama T, Tsuji S, Oda H Ann Nucl Med. 2017; 31(8):605-615.

PMID: 28689357 PMC: 5622915. DOI: 10.1007/s12149-017-1191-2.

Standardization of I--iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications.

Nakajima K, Verschure D, Okuda K, Verberne H Clin Transl Imaging. 2017; 5(3):255-263.

PMID: 28596948 PMC: 5437131. DOI: 10.1007/s40336-017-0230-2.

Influence of ROI definition on the heart-to-mediastinum ratio in planar I-MIBG imaging.

Klene C, Jungen C, Okuda K, Kobayashi Y, Helberg A, Mester J J Nucl Cardiol. 2016; 25(1):208-216.

PMID: 27804071 DOI: 10.1007/s12350-016-0708-8.

References

Nakajima K, Matsubara K, Ishikawa T, Motomura N, Maeda R, Akhter N . Correction of iodine-123-labeled meta-iodobenzylguanidine uptake with multi-window methods for standardization of the heart-to-mediastinum ratio. J Nucl Cardiol. 2007; 14(6):843-51. DOI: 10.1016/j.nuclcard.2007.08.002. View

Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, Yamada M . Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2011; 39(1):113-9. DOI: 10.1007/s00259-011-1963-1. View

Go A, Mozaffarian D, Roger V, Benjamin E, Berry J, Blaha M . Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2013; 129(3):e28-e292. PMC: 5408159. DOI: 10.1161/01.cir.0000441139.02102.80. View

Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M . HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010; 16(6):e1-194. DOI: 10.1016/j.cardfail.2010.04.004. View

Verberne H, Habraken J, van Eck-Smit B, Agostini D, Jacobson A . Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging. 2007; 35(3):547-53. PMC: 2275776. DOI: 10.1007/s00259-007-0611-2. View

Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S . A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013; 6(7):772-84. DOI: 10.1016/j.jcmg.2013.02.007. View

Sweeney M, Wathen M, Volosin K, Abdalla I, DeGroot P, Otterness M . Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation. 2005; 111(22):2898-905. DOI: 10.1161/CIRCULATIONAHA.104.526673. View

Lindstaedt M, Yazar A, Germing A, Fritz M, Holland-Letz T, Mugge A . Clinical outcome in patients with intermediate or equivocal left main coronary artery disease after deferral of surgical revascularization on the basis of fractional flow reserve measurements. Am Heart J. 2006; 152(1):156.e1-9. DOI: 10.1016/j.ahj.2006.03.026. View

Kline R, Swanson D, Wieland D, Thrall J, Gross M, Pitt B . Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981; 22(2):129-32. View

10.

Tung R, Zimetbaum P, Josephson M . A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol. 2008; 52(14):1111-21. DOI: 10.1016/j.jacc.2008.05.058. View

11.

Boogers M, Borleffs C, Henneman M, van Bommel R, van Ramshorst J, Boersma E . Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010; 55(24):2769-77. DOI: 10.1016/j.jacc.2009.12.066. View

12.

Arora R, Ferrick K, Nakata T, Kaplan R, Rozengarten M, Latif F . I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003; 10(2):121-31. DOI: 10.1067/mnc.2003.2. View

13.

Jacobson A, Senior R, Cerqueira M, Wong N, Thomas G, Lopez V . Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55(20):2212-21. DOI: 10.1016/j.jacc.2010.01.014. View

14.

Veltman C, Boogers M, Meinardi J, Al Younis I, Dibbets-Schneider P, van der Wall E . Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure. Eur J Nucl Med Mol Imaging. 2012; 39(10):1599-608. PMC: 3458210. DOI: 10.1007/s00259-012-2180-2. View

15.

Podrid P, Fuchs T, Candinas R . Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation. 1990; 82(2 Suppl):I103-13. View

16.

Slomka P, Patton J, Berman D, Germano G . Advances in technical aspects of myocardial perfusion SPECT imaging. J Nucl Cardiol. 2009; 16(2):255-76. DOI: 10.1007/s12350-009-9052-6. View

17.

Petretta M, Pellegrino T, Cuocolo A . The "gray zone" for the heart to mediastinum MIBG uptake ratio. J Nucl Cardiol. 2014; 21(5):921-4. DOI: 10.1007/s12350-014-9894-4. View

18.

Zaidi H, Koral K . Scatter modelling and compensation in emission tomography. Eur J Nucl Med Mol Imaging. 2004; 31(5):761-82. DOI: 10.1007/s00259-004-1495-z. View

19.

Small A, Prosser J, Motherwell D, McCurrach G, Fletcher A, Martin W . Downscatter correction and choice of collimator in 123I imaging. Phys Med Biol. 2006; 51(17):N307-11. DOI: 10.1088/0031-9155/51/17/N03. View

20.

Pellegrino T, Petretta M, De Luca S, Paolillo S, Boemio A, Carotenuto R . Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure. Eur J Nucl Med Mol Imaging. 2013; 40(10):1549-57. DOI: 10.1007/s00259-013-2461-4. View